Skip to the page

Data / Drug companies / Par Health USA, LLC

Par Health USA, LLC: 62 products in the FDA NDC directory, labeler code 42023

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Par Health USA, LLC (labeler code 42023) lists 62 products in the FDA National Drug Code Directory, covering 31 finished drugs by generic name. By type: 62 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on July 28, 2026.

The request: Watch Par Health USA, LLC (FDA labeler code 42023): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
42023
Products in commercial distribution
62
Packages
66
Finished drugs by generic name
31
Prescription products
62
Over the counter products
0
Controlled substance products
Schedule III 4, Schedule IV 1
Flagged as original packager
59 of 59 products that carry the flag
Started marketing in the last 12 months
3
Products with a marketing end date set
1
Earliest marketing start
October 1, 2007
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)4064.5%
Generic drugs (ANDA)2235.5%

Products by type

TypeProductsShare
Prescription drugs62100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection3962.9%
Injection, powder, lyophilized, for solution1016.1%
Injection, solution812.9%
Solution23.2%
Injection, powder, for solution11.6%
Injection, solution, concentrate11.6%
Capsule11.6%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Sugammadex sodium42023-935SolutionGeneric drugs (ANDA)July 28, 2026
Sugammadex sodium42023-830SolutionGeneric drugs (ANDA)July 28, 2026
Leuprolide acetate42023-259InjectionGeneric drugs (ANDA)June 30, 2026
Daptomycin42023-295Injection, powder, lyophilized, for solutionNew drug applications (NDA)October 27, 2025
Adrenalin (epinephrine in sodium chloride)42023-500InjectionNew drug applications (NDA)May 19, 2025
Adrenalin (epinephrine in sodium chloride)42023-721InjectionNew drug applications (NDA)May 14, 2025
Adrenalin (epinephrine in sodium chloride)42023-434InjectionNew drug applications (NDA)May 14, 2025
Adrenalin (epinephrine in sodium chloride)42023-273InjectionNew drug applications (NDA)May 14, 2025
Doxycycline42023-244Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)November 26, 2024
Naloxone Hydrochloride42023-224InjectionGeneric drugs (ANDA)November 5, 2024
Adrenalin (epinephrine in sodium chloride)42023-315InjectionNew drug applications (NDA)October 4, 2024
Pitocin42023-116InjectionNew drug applications (NDA)May 6, 2024
Ephedrine sulfate42023-243InjectionNew drug applications (NDA)January 31, 2024
Pitocin42023-116InjectionNew drug applications (NDA)December 22, 2023
Bivalirudin42023-622Injection, solutionNew drug applications (NDA)June 19, 2023
Prevduo42023-269InjectionNew drug applications (NDA)May 15, 2023
Posaconazole42023-195InjectionGeneric drugs (ANDA)January 1, 2023
Vasostrict42023-164InjectionNew drug applications (NDA)December 5, 2022
Vasostrict42023-237InjectionNew drug applications (NDA)December 15, 2021
Vasostrict42023-219InjectionNew drug applications (NDA)December 15, 2021
Calcitonin Salmon42023-205Injection, solutionGeneric drugs (ANDA)November 10, 2021
Ephedrine sulfate42023-243InjectionNew drug applications (NDA)January 31, 2021
Dexmedetomidine Hydrochloride42023-187Injection, solutionGeneric drugs (ANDA)December 4, 2020
Dexmedetomidine Hydrochloride42023-186Injection, solutionGeneric drugs (ANDA)December 4, 2020
Adrenalin42023-168InjectionNew drug applications (NDA)December 4, 2020

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.